Vertex Inc. (VERX)
Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic fibrosis (CF) drug market, including recent FDA approval for Alyftrek, ensures strong revenue and market expansion. The company's pipeline diversification, targeting diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, promises long-term growth.
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years.
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday. The post Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock appeared first on Investor's Business Daily.
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in the market for cystic fibrosis.
Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Cramer's Mad Dash: Vertex Pharmaceuticals
CNBC's Jim Cramer delivers his daily Mad Dash.
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study. The post Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
